A double-blind flexible dose study of escitalopram [Lexapro; Forest Laboratories] in pediatric patients with major depressive disorder.

Trial Profile

A double-blind flexible dose study of escitalopram [Lexapro; Forest Laboratories] in pediatric patients with major depressive disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2013

At a glance

  • Drugs Escitalopram (Primary)
  • Indications Depression; Depressive disorders; Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 13 Aug 2009 Status changed from active, no longer recruiting to completed.
    • 01 Jul 2009 Primary endpoint 'Children's Depression Rating Scale' has been met, as reported in the Journal of the American Academy of Child and Adolescent Psychiatry.
    • 07 May 2008 Results presented at APA 2008, according to a Forest Laboratories media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top